Healthcare & Life Sciences

Transcend Therapeutics

acquired
acquired
Stage
1
Investors

About

Transcend Therapeutics develops rapid-acting neuroplastic drugs targeting neuropsychiatric diseases such as PTSD, aiming to provide new treatment options for patients where current psychiatric medicines are ineffective.

Explore Transcend Therapeutics's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.